Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Logo

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd

000766.SZ

(1.0)
Stock Price

14,02 CNY

1.08% ROA

1.96% ROE

351.01x PER

Market Cap.

16.014.822.150,00 CNY

77.74% DER

0% Yield

3.29% NPM

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Stock Analysis

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE falls within an average range (1.42%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (0.81%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 DER

The stock maintains a fair debt to equity ratio (73%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (250), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

5 PBV

The stock's elevated P/BV ratio (6.33x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Revenue
Year Revenue Growth
1994 99.435.094
1995 132.489.388 24.95%
1996 163.867.686 19.15%
1997 241.070.629 32.03%
1998 270.986.777 11.04%
1999 284.909.562 4.89%
2000 504.187.311 43.49%
2001 100.434.798 -402%
2002 160.995.393 37.62%
2003 136.896.528 -17.6%
2004 99.872.056 -37.07%
2005 141.152.722 29.25%
2006 141.337.377 0.13%
2007 151.588.510 6.76%
2008 159.856.088 5.17%
2009 168.163.754 4.94%
2010 169.587.054 0.84%
2011 181.471.111 6.55%
2012 127.647.611 -42.17%
2013 147.781.836 13.62%
2014 208.414.737 29.09%
2015 197.558.721 -5.5%
2016 850.083.371 76.76%
2017 1.521.410.294 44.13%
2018 2.094.549.374 27.36%
2019 1.977.206.434 -5.93%
2020 1.111.802.396 -77.84%
2021 1.515.482.473 26.64%
2022 1.470.748.775 -3.04%
2023 1.263.003.976 -16.45%
2023 1.462.672.295 13.65%
2024 1.404.979.500 -4.11%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 710.000 100%
2014 1.667.800 57.43%
2015 262.687 -534.9%
2016 28.582.236 99.08%
2017 51.549.870 44.55%
2018 67.302.818 23.41%
2019 66.911.881 -0.58%
2020 50.329.629 -32.95%
2021 63.515.492 20.76%
2022 64.908.683 2.15%
2023 32.091.648 -102.26%
2023 44.930.643 28.58%
2024 40.803.524 -10.11%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 3.242.061
1995 6.395.451 49.31%
1996 9.180.542 30.34%
1997 15.639.591 41.3%
1998 21.753.829 28.11%
1999 35.717.998 39.1%
2000 62.410.945 42.77%
2001 154.700.368 59.66%
2002 47.869.687 -223.17%
2003 148.296.286 67.72%
2004 182.599.073 18.79%
2005 35.459.584 -414.95%
2006 35.182.262 -0.79%
2007 30.888.830 -13.9%
2008 30.620.652 -0.88%
2009 33.807.184 9.43%
2010 33.776.798 -0.09%
2011 41.769.721 19.14%
2012 11.815.996 -253.5%
2013 13.792.020 14.33%
2014 18.239.096 24.38%
2015 14.853.110 -22.8%
2016 44.128.206 66.34%
2017 39.710.006 -11.13%
2018 54.521.658 27.17%
2019 73.399.173 25.72%
2020 105.388.490 30.35%
2021 30.099.471 -250.13%
2022 25.512.795 -17.98%
2023 286.549.152 91.1%
2023 29.365.944 -875.79%
2024 -81.359.050 136.09%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd EBITDA
Year EBITDA Growth
1994 27.559.093
1995 51.535.560 46.52%
1996 79.894.793 35.5%
1997 112.941.983 29.26%
1998 127.589.356 11.48%
1999 116.892.139 -9.15%
2000 386.582.388 69.76%
2001 -475.944.628 181.22%
2002 91.468.829 620.34%
2003 -132.443.007 169.06%
2004 -221.713.009 40.26%
2005 28.701.985 872.47%
2006 23.753.496 -20.83%
2007 38.775.447 38.74%
2008 45.054.427 13.94%
2009 24.086.608 -87.05%
2010 42.217.354 42.95%
2011 26.411.792 -59.84%
2012 19.288.802 -36.93%
2013 30.226.383 36.19%
2014 36.024.326 16.09%
2015 29.273.914 -23.06%
2016 324.929.600 90.99%
2017 400.094.603 18.79%
2018 414.547.856 3.49%
2019 226.517.444 -83.01%
2020 -80.517.537 381.33%
2021 215.476.777 137.37%
2022 210.785.434 -2.23%
2023 132.834.460 -58.68%
2023 198.659.060 33.13%
2024 170.926.920 -16.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Gross Profit
Year Gross Profit Growth
1994 49.494.951
1995 82.016.245 39.65%
1996 116.187.942 29.41%
1997 165.681.949 29.87%
1998 156.709.994 -5.73%
1999 181.017.299 13.43%
2000 433.710.796 58.26%
2001 69.960.509 -519.94%
2002 121.561.866 42.45%
2003 86.755.570 -40.12%
2004 50.171.724 -72.92%
2005 82.376.324 39.09%
2006 75.310.688 -9.38%
2007 84.460.395 10.83%
2008 95.516.206 11.57%
2009 102.602.821 6.91%
2010 103.738.871 1.1%
2011 105.120.151 1.31%
2012 70.345.570 -49.43%
2013 75.547.522 6.89%
2014 129.038.596 41.45%
2015 101.111.178 -27.62%
2016 584.352.597 82.7%
2017 1.197.344.038 51.2%
2018 1.753.186.843 31.7%
2019 1.637.304.556 -7.08%
2020 887.500.867 -84.48%
2021 1.162.642.285 23.67%
2022 1.117.540.135 -4.04%
2023 960.600.195 -16.34%
2023 1.052.321.976 8.72%
2024 1.049.648.100 -0.25%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Net Profit
Year Net Profit Growth
1994 22.851.440
1995 46.863.379 51.24%
1996 65.995.819 28.99%
1997 95.484.014 30.88%
1998 83.310.421 -14.61%
1999 81.346.295 -2.41%
2000 241.914.921 66.37%
2001 -584.124.693 141.41%
2002 16.417.052 3658.04%
2003 -194.269.818 108.45%
2004 -245.679.276 20.93%
2005 8.476.142 2998.48%
2006 16.510.109 48.66%
2007 18.829.200 12.32%
2008 17.180.032 -9.6%
2009 29.790.955 42.33%
2010 12.018.506 -147.88%
2011 11.241.426 -6.91%
2012 3.856.634 -191.48%
2013 4.092.133 5.75%
2014 5.165.646 20.78%
2015 6.863.116 24.73%
2016 213.461.472 96.78%
2017 257.879.255 17.22%
2018 330.858.116 22.06%
2019 -2.042.936.121 116.2%
2020 -360.659.985 -466.44%
2021 35.273.252 1122.47%
2022 30.151.348 -16.99%
2023 19.094.899 -57.9%
2023 43.933.703 56.54%
2024 13.128.248 -234.65%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 1 0%
2001 -1 100%
2002 0 0%
2003 0 0%
2004 -1 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -2 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Free Cashflow
Year Free Cashflow Growth
1998 -75.581.288
1999 -144.129.238 47.56%
2000 -164.334.579 12.3%
2001 -756.751.394 78.28%
2002 55.399.086 1466%
2003 9.416.414 -488.32%
2004 14.758.455 36.2%
2005 18.187.409 18.85%
2006 -21.694.866 183.83%
2007 4.829.257 549.24%
2008 2.780.380 -73.69%
2009 66.799.691 95.84%
2010 18.849.601 -254.38%
2011 -16.075.104 217.26%
2012 -25.903.463 37.94%
2013 -54.692.369 52.64%
2014 -149.073.171 63.31%
2015 -189.019.981 21.13%
2016 -78.773.718 -139.95%
2017 -91.667.633 14.07%
2018 96.321.176 195.17%
2019 13.879.621 -593.98%
2020 61.549.439 77.45%
2021 112.853.524 45.46%
2022 174.423.220 35.3%
2023 86.113.017 -102.55%
2023 -4.967.724 1833.45%
2024 35.923.385 113.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Operating Cashflow
Year Operating Cashflow Growth
1998 -62.926.297
1999 -80.618.355 21.95%
2000 196.153.960 141.1%
2001 -740.340.453 126.5%
2002 72.704.529 1118.29%
2003 91.987.985 20.96%
2004 19.123.931 -381.01%
2005 35.735.307 46.48%
2006 -18.016.779 298.34%
2007 9.951.676 281.04%
2008 10.260.877 3.01%
2009 79.941.577 87.16%
2010 29.054.265 -175.15%
2011 -7.932.277 466.28%
2012 -6.494.214 -22.14%
2013 102.962.801 106.31%
2014 34.317.920 -200.03%
2015 -160.949.747 121.32%
2016 90.629.099 277.59%
2017 26.434.194 -242.85%
2018 170.722.975 84.52%
2019 74.861.078 -128.05%
2020 80.705.132 7.24%
2021 138.329.704 41.66%
2022 198.163.857 30.19%
2023 112.779.071 -75.71%
2023 0 0%
2024 49.306.477 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Capital Expenditure
Year Capital Expenditure Growth
1998 12.654.991
1999 63.510.883 80.07%
2000 360.488.539 82.38%
2001 16.410.941 -2096.64%
2002 17.305.443 5.17%
2003 82.571.570 79.04%
2004 4.365.476 -1791.47%
2005 17.547.898 75.12%
2006 3.678.088 -377.09%
2007 5.122.419 28.2%
2008 7.480.497 31.52%
2009 13.141.886 43.08%
2010 10.204.663 -28.78%
2011 8.142.827 -25.32%
2012 19.409.248 58.05%
2013 157.655.170 87.69%
2014 183.391.091 14.03%
2015 28.070.234 -553.33%
2016 169.402.817 83.43%
2017 118.101.827 -43.44%
2018 74.401.799 -58.74%
2019 60.981.456 -22.01%
2020 19.155.692 -218.35%
2021 25.476.180 24.81%
2022 23.740.636 -7.31%
2023 26.666.054 10.97%
2023 4.967.724 -436.79%
2024 13.383.092 62.88%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Equity
Year Equity Growth
1994 171.842.470
1995 181.317.849 5.23%
1996 191.231.669 5.18%
1997 602.892.469 68.28%
1998 689.390.351 12.55%
1999 1.046.960.819 34.15%
2000 1.076.882.630 2.78%
2001 475.053.152 -126.69%
2002 490.794.879 3.21%
2003 296.069.751 -65.77%
2004 36.636.873 -708.12%
2005 45.260.252 19.05%
2006 513.856.375 91.19%
2007 536.901.247 4.29%
2008 554.081.280 3.1%
2009 583.872.235 5.1%
2010 595.890.741 2.02%
2011 607.132.168 1.85%
2012 619.604.800 2.01%
2013 615.080.936 -0.74%
2014 659.496.066 6.73%
2015 2.246.374.709 70.64%
2016 4.161.447.169 46.02%
2017 4.418.536.153 5.82%
2018 4.747.756.390 6.93%
2019 2.665.984.258 -78.09%
2020 2.305.324.273 -15.64%
2021 2.339.312.451 1.45%
2022 2.368.501.241 1.23%
2023 2.317.833.158 -2.19%
2023 2.318.127.177 0.01%
2024 2.330.478.591 0.53%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Assets
Year Assets Growth
1994 233.519.788
1995 290.593.657 19.64%
1996 353.018.998 17.68%
1997 778.316.280 54.64%
1998 923.397.747 15.71%
1999 1.333.152.592 30.74%
2000 2.257.839.315 40.95%
2001 1.469.138.110 -53.68%
2002 1.530.786.036 4.03%
2003 1.440.920.236 -6.24%
2004 1.091.068.074 -32.07%
2005 1.106.771.435 1.42%
2006 795.902.547 -39.06%
2007 809.427.666 1.67%
2008 811.589.207 0.27%
2009 869.227.902 6.63%
2010 902.596.710 3.7%
2011 879.821.693 -2.59%
2012 894.890.628 1.68%
2013 1.106.992.392 19.16%
2014 1.285.585.281 13.89%
2015 4.155.687.059 69.06%
2016 5.303.516.233 21.64%
2017 5.726.837.493 7.39%
2018 5.997.069.913 4.51%
2019 4.698.048.449 -27.65%
2020 4.977.076.111 5.61%
2021 4.640.791.421 -7.25%
2022 4.685.114.987 0.95%
2023 4.466.267.721 -4.9%
2023 4.520.353.793 1.2%
2024 4.599.572.689 1.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Liabilities
Year Liabilities Growth
1994 61.677.318
1995 109.275.808 43.56%
1996 161.787.329 32.46%
1997 175.423.810 7.77%
1998 234.007.395 25.03%
1999 286.191.772 18.23%
2000 1.180.956.684 75.77%
2001 994.084.956 -18.8%
2002 1.039.991.155 4.41%
2003 1.144.850.484 9.16%
2004 1.054.431.201 -8.58%
2005 1.061.511.182 0.67%
2006 282.046.172 -276.36%
2007 272.526.418 -3.49%
2008 257.507.927 -5.83%
2009 285.355.666 9.76%
2010 306.705.968 6.96%
2011 272.689.525 -12.47%
2012 275.285.828 0.94%
2013 491.911.455 44.04%
2014 626.089.214 21.43%
2015 1.909.312.349 67.21%
2016 1.142.069.063 -67.18%
2017 1.308.301.339 12.71%
2018 1.249.313.522 -4.72%
2019 2.032.064.190 38.52%
2020 2.671.751.837 23.94%
2021 2.301.478.969 -16.09%
2022 2.316.613.744 0.65%
2023 2.148.434.563 -7.83%
2023 2.137.851.631 -0.5%
2024 2.206.979.863 3.13%

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.44
Net Income per Share
0.05
Price to Earning Ratio
351.01x
Price To Sales Ratio
11.54x
POCF Ratio
145.87
PFCF Ratio
208.45
Price to Book Ratio
6.87
EV to Sales
12.65
EV Over EBITDA
100.59
EV to Operating CashFlow
159.98
EV to FreeCashFlow
228.61
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
16,01 Bil.
Enterprise Value
17,56 Bil.
Graham Number
1.6
Graham NetNet
-1.39

Income Statement Metrics

Net Income per Share
0.05
Income Quality
2.41
ROE
0.02
Return On Assets
0.01
Return On Capital Employed
0.02
Net Income per EBT
0.79
EBT Per Ebit
0.59
Ebit per Revenue
0.07
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.73
Operating Profit Margin
0.07
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
1.82
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.11
Free CashFlow per Share
0.08
Capex to Operating CashFlow
0.3
Capex to Revenue
0.02
Capex to Depreciation
1.81
Return on Invested Capital
0.02
Return on Tangible Assets
0.01
Days Sales Outstanding
143.14
Days Payables Outstanding
130.19
Days of Inventory on Hand
383.49
Receivables Turnover
2.55
Payables Turnover
2.8
Inventory Turnover
0.95
Capex per Share
0.03

Balance Sheet

Cash per Share
0,27
Book Value per Share
2,48
Tangible Book Value per Share
2.08
Shareholders Equity per Share
2.41
Interest Debt per Share
1.96
Debt to Equity
0.78
Debt to Assets
0.39
Net Debt to EBITDA
8.87
Current Ratio
1.88
Tangible Asset Value
2,01 Bil.
Net Current Asset Value
-1,00 Bil.
Invested Capital
1955631072
Working Capital
0,56 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,53 Bil.
Average Payables
0,15 Bil.
Average Inventory
387642142
Debt to Market Cap
0.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Dividends
Year Dividends Growth
2001 1

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Profile

About Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products primarily focus on the rheumatism, digestion, cancer, and gynecology fields. The company offers traditional Chinese medicines, such as gynecological, rheumatic and bone pain, urology, detoxification, cardio-cerebral, digestive, respiratory, diabetes, and pediatric medication products, as well as anti-tumor drugs, prescription and OTC drugs, and Western medicines. The company offers its products in the form of capsules, tablets, injections, liquids, etc. Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. was founded in 1990 and is based in Tonghua, China.

CEO
Mr. Hongjun Zhan
Employee
1.696
Address
No. 999, Jinma Road
Tonghua, 134001

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Executives & BODs

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Executives & BODs
# Name Age
1 Mr. Hongjun Zhan
General Manager
70
2 Mr. Yu Jing
Deputy GM & Non-Independent Director
70
3 Mr. Yu Jun
Deputy GM & Chief Financial Officer
70
4 Mr. Weilin Jia
Secretary & Deputy GM
70

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Competitors